Table 2. Presence of immune cells in tumors and peripheral blood of STSA-1 xenografted mice 7 d after LIVP6.1.1 or PBS-treatments.
|
Immune cells in [%] |
PBS/ tumor |
LIVP6.1.1/ tumor |
P-value PBS vs LIVP6.1.1 tumor |
PBS/ blood |
LIVP6.1.1/ blood |
|---|---|---|---|---|---|
|
MHCII+CD45+ |
0.66% ± 0.23% |
2.67% ± 0.35% |
** (p = 0.002) |
nt |
nt |
|
F4/80+CD45+ |
0.77% ± 0.47% |
4.61% ± 0.25% |
** (p = 0.001) |
nt |
nt |
|
CD11b+Gr-1int |
0.2% ± 0.08% |
3% ± 0.69% |
* (p = 0.018) |
nt |
nt |
|
CD11b+Gr-1high |
0.27% ± 0.08% |
2.48% ± 0.70% |
* (p = 0.03) |
27.39% ± 7.67% |
25.49% ± 3.96% |
MHCII+CD45+ (mainly B cells, macrophages and dendritic cells), F4/80+CD45+; (macrophages), Gr-1highCD11b+ (Myeloid-derived suppressor cells, MDSCs, granulocytes) and Gr-1intCD11b+ (MDSCs, monocytes). Experiments were done twice with at least 3 mice per group. The data are presented as mean values +/− SD. The statistical significance was analyzed using two-tailed unpaired Student's test (** p < 0.01, *p < 0.05). nt, not tested.